Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities (2018 - 2019)

Black Diamond Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $200.6 million for Q4 2019.

  • For Q4 2019, Preferred Stock Liabilities rose 230.05% year-over-year to $200.6 million; the TTM value through Dec 2019 reached $200.6 million, up 230.05%, while the annual FY2019 figure was $200.6 million, 230.05% up from the prior year.
  • Preferred Stock Liabilities reached $200.6 million in Q4 2019 per BDTX's latest filing, up from $115.8 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $200.6 million in Q4 2019 to a low of $60.8 million in Q4 2018.